Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma

Macrophage migration inhibitory factor (MIF) may contribute to multiple aspects of tumor progression, including control of cell proliferation, differentiation, cell survival and angiogenesis. However, the potential roles of MIF in regulating hepatocellular carcinoma (HCC) tumor cell migration and the expression of angiogenic factors by HCC tumor cells have not been studied yet. In our study, we reported that intracellular MIF mRNA and protein were overexpressed in HCC tissues compared to nontumor tissues by using in situ hybridization and immunohistochemic staining. HCC tumor cell lines also secreted large amounts of MIF into the supernatants of tumor cell culture. To assess the role of MIF in HCC, we employed the transwell invasion chamber to study the effect of MIF on tumor cell migration. Our results showed that recombinant MIF and the supernatants of tumor cell line culture could enhance the invasion and migration of HCC cells. This effect can be inhibited by the addition of a neutralizing anti‐MIF antibody. We observed that increased MIF serum levels correlated with higher levels of interleukin‐8 (IL‐8) in the sera of patients with HCC than in normal volunteers. We therefore hypothesized that MIF may regulate the production of angiogenic factors by HCC cells. To test this hypothesis, we examined the effect of MIF treatment on vascular endothelial growth factor (VEGF) and IL‐8 expression by HCC cell lines. MIF induced a significant dose‐dependent increase in IL‐8 and VEGF production. Taken together, our results indicated that MIF may act as an autocrine‐acting factor that stimulates angiogenesis and metastasis in HCC by promoting expression of angiogenic factors and migration of tumor cells. A more detailed understanding of the MIF regulatory mechanisms involved may provide insight into new direction in the treatment of HCC. © 2003 Wiley‐Liss, Inc.

[1]  Barbara Magi,et al.  Protein expression profiles in human breast ductal carcinoma and histologically normal tissue , 1997, Electrophoresis.

[2]  N. Hayashi,et al.  Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. , 1996, Cancer research.

[3]  J. Bernhagen,et al.  MIF as a glucocorticoid-induced modulator of cytokine production , 1995, Nature.

[4]  K. Tracey,et al.  MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia , 1993, Nature.

[5]  P. Lollini,et al.  The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. , 2000, The American journal of pathology.

[6]  R. Bucala,et al.  An Essential Role for Macrophage Migration Inhibitory Factor (MIF) in Angiogenesis and the Growth of a Murine Lymphoma , 1999, Molecular medicine.

[7]  R. Swerlick,et al.  Transforming growth factor‐α‐induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP‐2‐dependent DNA binding and transactivation , 1997, The EMBO journal.

[8]  J. Bernhagen,et al.  Purification, bioactivity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF). , 1994, Biochemistry.

[9]  L. Ellis,et al.  The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.

[10]  R. Whyte,et al.  Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma , 1994, The Journal of experimental medicine.

[11]  R. Bucala,et al.  Macrophage migration inhibitory factor is an important mediator in the pathogenesis of gastric inflammation in rats. , 2001, Gastroenterology.

[12]  M. Karkkainen,et al.  Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis , 2000, Oncogene.

[13]  R. Poon,et al.  Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. , 1999, Annals of surgery.

[14]  K. Meyer-Siegler,et al.  Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. , 1996, Urology.

[15]  M. Suzuki,et al.  High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. , 1999, Biochemical and biophysical research communications.

[16]  M. Burdick,et al.  Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. , 1996, The Journal of clinical investigation.

[17]  H. Dosaka-akita,et al.  Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung , 2000, Cancer.

[18]  Lothar Schweigerer,et al.  Vascular endothelial growth factor expression in human neuroblastoma: Up‐regulation by hypoxia , 1999, International journal of cancer.

[19]  K. Tanikawa,et al.  Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. , 1998, Human pathology.

[20]  Erwin G. Van Meir,et al.  Upregulation of Interleukin 8 by Oxygen-deprived Cells in Glioblastoma Suggests a Role in Leukocyte Activation, Chemotaxis, and Angiogenesis , 1997, The Journal of experimental medicine.

[21]  Y. Yang,et al.  Identification of macrophage migration inhibitory factor as a potent endothelial cell growth-promoting agent released by ectopic human endometrial cells. , 2000, The Journal of clinical endocrinology and metabolism.

[22]  S. Meijer,et al.  Isolation and purification of large quantities of fresh human Kupffer cells, which are cytotoxic against colon carcinoma , 1995, Hepatology.

[23]  Anthony J. Guidi,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. , 1995, Human pathology.

[24]  J. Bruix,et al.  Treatment of hepatocellular carcinoma. , 2006, Critical reviews in oncology/hematology.

[25]  S. Nagataki,et al.  Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses , 1994, Cancer.

[26]  C. Bucana,et al.  Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. , 1994, Cancer research.

[27]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.

[28]  M. Volm,et al.  Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. , 1996, British Journal of Cancer.

[29]  S. Fan,et al.  Serum Vascular Endothelial Growth Factor Predicts Venous Invasion in Hepatocellular Carcinoma : A Prospective Study , 2001, Annals of surgery.

[30]  V. Barr,et al.  Reduced expression of insulin-like growth factor I receptors in MCF-7 breast cancer cells leads to a more metastatic phenotype. , 2002, Cancer research.

[31]  Y. Sasaki,et al.  Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase , 1999, Clinical & Experimental Metastasis.

[32]  R. Strieter,et al.  Interleukin-8 as a macrophage-derived mediator of angiogenesis. , 1992, Science.

[33]  E. Manseau,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. , 1993, Cancer research.

[34]  M. Abe,et al.  Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. , 2001, Cancer letters.

[35]  S. Fan,et al.  Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. , 2001, American journal of clinical pathology.

[36]  M. Kojiro,et al.  Expression and function of interleukin-8 in human hepatocellular carcinoma. , 2001, International journal of oncology.

[37]  M. Kojiro,et al.  Expression of vascular endothelial growth factor in human hepatocellular carcinoma , 1998, Hepatology.

[38]  J. Bernhagen,et al.  The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor , 1994, The Journal of experimental medicine.

[39]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[40]  G. Hannon,et al.  A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity , 1999, The Journal of experimental medicine.

[41]  O. Yokosuka,et al.  Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients , 1995, Hepatology.

[42]  Harold E. Dvorak,et al.  Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels , 1991, The Journal of experimental medicine.

[43]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[44]  R. Bucala,et al.  Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). , 2000, Seminars in cancer biology.